Ignite Creation Date:
2024-05-05 @ 6:58 PM
Last Modification Date:
2024-10-26 @ 9:38 AM
Study NCT ID:
NCT00574834
Status:
TERMINATED
Last Update Posted:
2019-09-12
First Post:
2007-12-13
Brief Title:
Mechanisms of Ramipril Reduction in the Onset of Type 2 Diabetes
Sponsor:
University of Maryland Baltimore
Organization:
University of Maryland Baltimore
Study Overview
Official Title:
Mechanisms of Reduced Ramipril on the Onset of Type 2 Diabetes Mellitis
Status:
TERMINATED
Status Verified Date:
2019-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Lack of funding
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The study will be focused on determining the integrated in-vivo mechanisms responsible for Ramiprils effects on delaying type 2 diabetes and restoring normal blood sugar levels glycemia in patients with impaired glucose tolerance
Hypothesis - Ramipril effects will delay the onset of type 2 diabetes and restore normal glycemia in patients with impaired glucose tolerance
Hypothesis - Ramipril effects will delay the onset of type 2 diabetes and restore normal glycemia in patients with impaired glucose tolerance
Detailed Description:
Several studies have demonstrated that therapeutic agents used to reduce glucose levels andor weight can delay the onset of type 2 diabetes Intriguingly angiotensin converting enzyme ACE inhibitors or angiotensin receptor blockers ARB also result in reduction in the onset of type 2 DM The most striking effect was found with Ramipril in the HOPE study The onset of new type 2 DM was reduced by 34 p0001 as compared to placebo Furthermore the results of the DREAM trial demonstrate that Ramipril at a dose of 15 mg can significantly reverse impaired glucose tolerance However the mechanisms underlying Ramipril effects to delay type 2 diabetes are not known
The proposal will be focused on determining the integrated in-vivo mechanisms responsible for Ramiprils effects on delaying type 2 DM and restoring normal glycemia in patients with impaired glucose tolerance
The specific aims of the project are
to determine the effect of Ramipril on insulin resistance at the level of the liver and peripheral tissues
to determine the effect of Ramipril on endothelial function
to determine the effects of Ramipril on insulin secretion and
to determine the effects of Ramipril on substrate flux lipolysis and inflammatory cytokines
The proposal will be focused on determining the integrated in-vivo mechanisms responsible for Ramiprils effects on delaying type 2 DM and restoring normal glycemia in patients with impaired glucose tolerance
The specific aims of the project are
to determine the effect of Ramipril on insulin resistance at the level of the liver and peripheral tissues
to determine the effect of Ramipril on endothelial function
to determine the effects of Ramipril on insulin secretion and
to determine the effects of Ramipril on substrate flux lipolysis and inflammatory cytokines
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None